CONMED Corporation (CNMD) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. Analyst target reached at $37.01 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3).
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture... Read more
Sell if holding. Analyst target reached at $37.01 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3). Chart setup: Death cross but MACD improving, RSI 52. Score 5.3/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — CONMED Corporation
Latest news
- CONMED ($CNMD) Releases Q1 2026 Earnings - Quiver Quantitative — Quiver Quantitative neutral
- Conmed (CNMD) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance — Yahoo Finance positive
- CONMED’s (NYSE:CNMD) Q1 CY2026 Sales Beat Estimates - StockStory — StockStory positive
- Earnings Flash (CNMD) CONMED Corporation Posts Q1 Adjusted EPS $0.89 per Share, vs. FactSet Est of $0.82 - marketscreene — marketscreener.com positive
- CONMED (CNMD) Stock: Price Action Analysis | Q4 2025: EPS Beats Forecasts - Most Watched Stocks - Cổng thông tin điện tử — Cổng thông tin điện tử Tỉnh Sơn La positive
Generated 2026-05-20T22:01:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $37.01 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3). Chart setup: Death cross but MACD improving, RSI 52. Prior stop was $34.42. Score 5.3/10, moderate confidence.
Take-profit target: $39.38 (+6.4% upside). Prior stop was $34.42. Stop-loss: $34.42.
Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3); Consecutive earnings misses (3).
CONMED Corporation trades at a P/E of 20.4 (forward 7.5). TrendMatrix value score: 7.7/10. Verdict: Sell.
11 analysts cover CNMD with a consensus score of 2.5/5. Average price target: $40.
What does CONMED Corporation do?CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical...
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.